日报更新时间：06-24 15:34
周报更新时间：06-25 22:35
今开价：75.7
最高价：76.14
成交量：709595.0
昨收价：75.63
最低价：75.21
最新价：75.89
中文名称：因塞特
英文名称：Incyte
行业：医疗
简介：因塞特医疗公司是一家生物制药公司，主要从事发现、开发和商业化拥有所有权的小分子药物，以应对严重未满足的医疗需要
电话：1-302-4986700
因塞特医疗（英赛德公司）开发主治HIV、癌症与炎症疾病药物发现，从事基因资讯提供，并结合基因资料与强大的软体工具，使研究人员可以分析比较来自有机活体的数百万种基因组合，加速开发新的疗法。因塞特医疗Incyte Corporation(INCY)产品百科： JAKAFI——治疗骨髓纤维化和真性红细胞增多癌症，商用阶段，因塞特医疗公司通过专业药店网络以及批发销售其JAKAFI产品。 Ruxolitinib Cream——用于斑秃的治疗，目前处于II期临床试验阶段。 INCB52793——用于治疗晚期恶性肿瘤，目前处于I/II期临床试验阶段。 Baricitinib——处于类风湿关节炎治疗的III期临床试验阶段；同时处于牛皮癣和糖尿病肾病的II期临床试验阶段；同时处于特应性皮炎治疗的II期临床试验阶段。 INCB39110——与osimertinib结合治疗肺癌，目前处于I/II期临床试验阶段；与pembrolizumab结合治疗晚期恶性肿瘤，目前也处于I/II期临床试验阶段；同时处于移植物抗宿主病治疗的II期临床试验阶段。 Epacadostat——用于多种肿瘤治疗，目前处于II期临床试验阶段；处于治疗非小细胞肺癌以及晚期黑色素瘤的I/II期临床试验阶段。 INCB54329 (BRD) and INCB53914 (PIM)——治疗晚期恶性肿瘤的I/II期临床试验阶段。 INCB50465 (PI3Kd)——治疗B-细胞恶性肿瘤和实体瘤的I/II期临床试验阶段。 INCB54828 (FGFR) and INCSHR1210——处于实体瘤治疗的I/II期临床试验阶段。 Capmatinib——处于治疗非小细胞肺癌、胶质细胞瘤和肝癌的II期临床试验阶段。因塞特医疗（Incyte Corporation）与诺华公司（Novartis International Pharmaceutical Ltd.）、礼来公司（Eli Lilly and Company）、安帝君斯（Agenus Inc.）、辉瑞制药（Pfizer Inc.）、Merus N.V.、Calithera Biosciences, Inc.、中国江苏恒瑞医药股份有限公司（Jiangsu Hengrui Medicine Co., Ltd.）以及Abramson Cancer Center签订了合作协议。 2015年9月，因塞特医疗宣布以7.95亿美金获得江苏恒瑞医药股份有限公司(SH:600276)的PD-1单克隆抗体（SHR-1210）的独家开发和商业化权利。 Novartis 收购了Incyte的c-Met 抑制剂—— capmatinib (INC280, INCB028060)。 2017年4月16日，由于安全性和剂量原因，FDA拒绝了因塞特医疗每日一次的类风湿关节炎药物巴利西肽（baricitinib），指示公司股价暴跌超过10%。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-16 | Flannelly Barry P | Officer | Sell | 959 | 79.91 |
| 2019-07-14 | Swain (Paula J) | Officer | Sell | 2500 | 80.00 |
| 2019-07-14 | Swain (Paula J) | Officer | Sell | 639 | 81.39 |
| 2019-07-14 | Swain (Paula J) | Officer | Buy | 2500 | 64.55 |
| 2019-07-14 | Trower (Paul) | Officer | Sell | 291 | 81.39 |
| 2019-07-14 | Hoppenot Herve | Chief Executive Officer | Sell | 2400 | 81.39 |
| 2019-07-14 | Yao (Wenqing) | Officer | Sell | 639 | 81.39 |
| 2019-07-14 | Flannelly Barry P | Officer | Sell | 430 | 81.39 |
| 2019-07-14 | Stein (Steven H.) | Officer | Sell | 409 | 81.39 |
| 2019-07-04 | Trower (Paul) | Officer | Sell | 148 | 85.28 |
| 2019-07-04 | Swain (Paula J) | Officer | Sell | 404 | 85.28 |
| 2019-07-04 | Yao (Wenqing) | Officer | Sell | 404 | 85.28 |
| 2019-07-04 | Stein (Steven H.) | Officer | Sell | 267 | 85.28 |
| 2019-07-04 | Flannelly Barry P | Officer | Sell | 273 | 85.28 |
| 2019-07-04 | Iyengar (Vijay K) | Officer | Sell | 273 | 85.28 |
| 2019-07-04 | Hoppenot Herve | Chief Executive Officer | Sell | 1552 | 85.28 |
| 2019-07-01 | Stein (Steven H.) | Officer | Buy | 6761 | -- |
| 2019-07-01 | Yao (Wenqing) | Officer | Sell | 619 | 85.01 |
| 2019-07-01 | Flannelly Barry P | Officer | Buy | 6761 | -- |
| 2019-07-01 | Hoppenot Herve | Chief Executive Officer | Buy | 39648 | -- |
| 2019-07-01 | Swain (Paula J) | Officer | Sell | 619 | 85.01 |
| 2019-07-01 | Hoppenot Herve | Chief Executive Officer | Sell | 2410 | 85.01 |
| 2019-07-01 | Pasquale (Maria E) | General Counsel | Sell | 470 | 85.01 |
| 2019-07-01 | Pasquale (Maria E) | General Counsel | Buy | 6761 | -- |
| 2019-07-01 | Yao (Wenqing) | Officer | Buy | 6761 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Goldman Sachs Group Inc | 2335755 | 1.09% | 723608 | 44.88% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 7658026 | 3.57% | -1148084 | -13.04% | 2019-03-31 |
| Capital Research & Mgmt Co - Division 3 | 7801907 | 3.64% | 163505 | 2.14% | 2019-03-31 |
| State Street Corporation | 8118520 | 3.79% | 495760 | 6.50% | 2019-03-31 |
| Capital Research and Management Company | 9369616 | 4.36% | -1365678 | -12.72% | 2019-07-31 |
| Wellington Management Company LLP | 15081000 | 7.03% | -533825 | -3.42% | 2019-03-31 |
| BlackRock Inc | 15453453 | 7.21% | 190491 | 1.25% | 2019-03-31 |
| Vanguard Group Inc | 19135086 | 8.92% | 316847 | 1.68% | 2019-03-31 |
| Baker Bros Advisors LP | 34271827 | 15.98% | 20220 | 0.06% | 2019-03-31 |
| BlackRock Fund Advisors | 6466667 | 3.01% | 19522 | 0.30% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 5095522 | 2.37% | 30765 | 0.61% | 2019-07-31 |
| Sands Capital Management, LLC | 4340795 | 2.02% | -23600 | -0.54% | 2019-03-31 |
| Geode Capital Management, LLC | 2508013 | 1.17% | -2213199 | -46.88% | 2019-03-31 |
| Invesco Capital Management LLC | 2728975 | 1.27% | -168973 | -5.83% | 2019-07-31 |
| State Street Global Advisors | 2974086 | 1.38% | 9480 | 0.32% | 2019-07-31 |
| BB Biotech AG | 3620000 | 1.69% | -188322 | -4.95% | 2019-03-31 |
| Bellevue Asset Management AG | 3652650 | 1.70% | -40000 | -1.08% | 2019-07-31 |
| Matrix Capital Management Company, LLC | 4011847 | 1.87% | -5000 | -0.12% | 2019-03-31 |
| UBS Asset Mgmt Americas Inc | 4038766 | 1.88% | -186868 | -4.42% | 2019-03-31 |
| Dodge & Cox | 4255350 | 1.98% | 15250 | 0.36% | 2019-03-31 |
| Amvescap Plc. | 3078281 | 1.44% | -36902 | -1.18% | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 5588786 | 2.61% | 7572 | 0.14% | 2019-05-31 |
| BlackRock Japan Co Ltd | 2603514 | 1.21% | 2603514 | -- | 2019-04-30 |
| Manning & Napier Group, LLC | 2324273 | 1.09% | -2291216 | -49.64% | 2018-12-31 |
| SSGA Funds Management Inc | 2048572 | 0.96% | 43949 | 2.19% | 2018-11-30 |
| UBS Group AG | 4561003 | 2.14% | 4348199 | 2043.29% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 4259711 | 2.00% | -420056 | -8.98% | 2018-06-30 |
| UBS Securities LLC | 4561003 | 2.14% | 4348199 | 2043.29% | 2018-06-30 |
| State Street Corp | 7494341 | 3.53% | 92337 | 1.25% | 2018-06-30 |
| State Street Global Advisors (Aus) Ltd | 2028110 | 0.95% | 48568 | 2.45% | 2018-09-12 |
| Invesco PowerShares Capital Mgmt LLC | 2487199 | 1.17% | 783356 | 45.98% | 2018-06-30 |
| Northern Trust Investments N A | 1933597 | 0.91% | 64282 | 3.44% | 2018-06-30 |
| Citadel Advisors Llc | 1887200 | 0.89% | 1264002 | 202.83% | 2018-06-30 |
| Pictet Asset Management SA | 1815728 | 0.85% | 418444 | 29.95% | 2018-06-30 |
| Goldman, Sachs & Co. | 1338340 | 0.63% | -466003 | -25.83% | 2018-06-30 |
| Capital World Investors | 5073600 | 2.39% | -1043824 | -17.06% | 2018-03-31 |
| Franklin Advisers Inc | 1520631 | 0.72% | -1102094 | -42.02% | 2018-03-31 |
| J.P. Morgan Investment Management Inc | 1675688 | 0.79% | -37784 | -2.21% | 2018-03-31 |
| Fidelity Management and Research Company | 2203453 | 1.04% | 222032 | 11.21% | 2018-03-31 |
| NORGES BANK | 2283505 | 1.08% | 679491 | 42.36% | 2017-12-31 |
| Orbimed Advisors, LLC | 1476000 | 0.70% | -187400 | -11.27% | 2017-09-30 |
| Vanguard Specialized Funds | 9466973 | 4.48% | -2168935 | -18.64% | 2017-12-31 |
| Jennison Associates LLC | 1633173 | 0.77% | 319191 | 24.29% | 2017-09-30 |
| Invesco Advisers, Inc | 1414006 | 0.69% | 5391 | 0.38% | 2017-06-30 |
| Brown Capital Management, LLC | 2647505 | 1.41% | -7324 | -0.28% | 2016-09-30 |
| Capital Guardian Trust Company | 1936960 | 1.03% | -58006 | -2.91% | 2016-09-30 |
| Columbia Mangmt Investment Advisers, LLC | 1335459 | 0.71% | 12786 | 0.97% | 2016-09-30 |
| American Century Inv Mgt Inc | 1262158 | 0.67% | 104343 | 9.01% | 2016-09-30 |
| BlackRock,Inc. | 8940287 | 4.00% | 793808083 | -- | 1999-11-30 |
| The Vanguard Group | 9223856 | 4.00% | 818986174 | -- | 1999-11-30 |
| Vanguard Specialized FundsVanguard Health Care Fund | 10174343 | 4.00% | 903379915 | 0.10% | 1999-11-30 |
| Julian C. Baker | 14952708 | 4.00% | 1327650943 | 0.10% | 1999-11-30 |
| Wellington Management GroupLLP | 17035043 | 4.00% | 1512541468 | 0.10% | 1999-11-30 |
| T. Rowe Price Associates,Inc. | 20152359 | 4.00% | 1789327956 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity | 1183685 | 0.55% | -- | -- | 2019-06-30 |
| Vanguard Health Care Fund | 11113220 | 5.17% | -- | -- | 2019-03-31 |
| American Funds New Perspective Fund | 5108900 | 2.38% | -63728 | -1.23% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 5018653 | 2.33% | 30752 | 0.62% | 2019-06-30 |
| Vanguard Mid-Cap Index Fund | 4440147 | 2.06% | 70080 | 1.60% | 2019-06-30 |
| Vanguard 500 Index Fund | 3503609 | 1.63% | 44572 | 1.29% | 2019-06-30 |
| UBS: Global Equity-UBS | 3037802 | 1.41% | -- | -- | 2019-03-31 |
| iShares Nasdaq Biotechnology ETF | 2116848 | 0.98% | 22032 | 1.05% | 2019-07-30 |
| Dodge & Cox Stock Fund | 1995900 | 0.93% | -- | -- | 2019-06-30 |
| SPDR | 1979996 | 0.92% | 1819 | 0.09% | 2019-07-31 |
| Invesco QQQ Trust | 1925969 | 0.90% | 1701 | 0.09% | 2019-07-31 |
| First Trust NYSE Arca Biotech Fund | 1183896 | 0.55% | -2853 | -0.24% | 2019-07-31 |
| Vanguard Growth Index Fund | 1302449 | 0.61% | 46011 | 3.66% | 2019-06-30 |
| iShares Core S&P 500 ETF | 1311968 | 0.61% | -648 | -0.05% | 2019-07-30 |
| American Funds IS | 1330900 | 0.62% | -- | -- | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 1477454 | 0.69% | -103100 | -6.52% | 2019-06-30 |
| Vanguard Institutional Index Fund | 1661858 | 0.77% | -8532 | -0.51% | 2019-06-30 |
| T. Rowe Price Mid-Cap Growth Fund | 1800000 | 0.84% | -- | -- | 2019-06-30 |
| Health Care Select Sector SPDR | 941032 | 0.44% | -4522 | -0.48% | 2019-06-28 |
| Vanguard Mid-Cap Growth Index Fund | 1112645 | 0.52% | 7972 | 0.72% | 2019-05-31 |
| iShares Core S&P US Total Market ETF | 1316121 | 0.61% | 1188 | 0.09% | 2019-05-30 |
| iShares S&P 500 ETF | 1316121 | 0.61% | 1188 | 0.09% | 2019-05-30 |
| iShares Core S&P 500 ETF (CAD-Hedged) | 1316121 | 0.61% | 1188 | 0.09% | 2019-05-30 |
| iShares Core MSCI Kokusai ETF | 1316121 | 0.61% | 1188 | 0.09% | 2019-05-30 |
| iShares MSCI World ETF | 1301757 | 0.61% | -2700 | -0.21% | 2019-04-25 |
| T. Rowe Price Mid-Cap Value Fund | 1198500 | 0.56% | 225500 | 23.18% | 2018-12-31 |
| VA CollegeAmerica New Perspective Fd | 5394600 | 2.52% | -- | -- | 2018-12-31 |
| OH Putnam Fidelity Spartan 500 Index | 1323237 | 0.62% | 38286 | 2.98% | 2019-01-31 |
| Oppenheimer Global Fund | 933760 | 0.44% | -- | -- | 2018-11-30 |
| American Funds Capital World Gr&Inc Fd | 1761800 | 0.83% | 114200 | 6.93% | 2018-06-30 |
| T. Rowe Price Growth Stock Fund | 2715600 | 1.28% | -160700 | -5.59% | 2018-03-31 |
| VA CollegeAmerica Capital Wld Gr & Inc | 1761800 | 0.83% | 114200 | 6.93% | 2018-06-30 |
| VA CollegeAmerica Cap World G/I 529E | 1761800 | 0.83% | 114200 | 6.93% | 2018-06-30 |
| T. Rowe Price Mid-Cap Value | 866400 | 0.41% | 866400 | -- | 2018-06-30 |
| Vanguard Health Care Inv | 10657473 | 5.02% | 1190500 | 12.58% | 2018-06-30 |
| VA CollegeAmerica New Perspective 529E | 4885500 | 2.30% | -1500200 | -23.49% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 4526365 | 2.13% | 18404 | 0.41% | 2018-07-31 |
| Vanguard Mid Cap Index I | 4276142 | 2.01% | 33605 | 0.79% | 2018-07-31 |
| Vanguard 500 Index Inv | 3186958 | 1.50% | 4645 | 0.15% | 2018-07-31 |
| T. Rowe Price Health Sciences | 2421428 | 1.14% | 149000 | 6.56% | 2018-06-30 |
| iShares Nasdaq Biotechnology | 2404836 | 1.02% | -4578 | -0.19% | 2018-09-12 |
| T. Rowe Price Mid-Cap Growth | 2000000 | 0.94% | 750000 | 60.00% | 2018-06-30 |
| PowerShares QQQ ETF | 1736689 | 0.75% | -6720 | -0.39% | 2018-09-13 |
| Vanguard Institutional Index I | 1700559 | 0.80% | 743 | 0.04% | 2018-07-31 |
| American Funds NVIT Growth-Income II | 1330900 | 0.63% | -- | -- | 2018-06-30 |
| Vanguard Growth Index Inv | 1269020 | 0.60% | -3540 | -0.28% | 2018-07-31 |
| Fidelity Spartan | 1171933 | 0.55% | 13823 | 1.19% | 2018-07-31 |
| Vanguard Mid-Cap Growth ETF | 1094353 | 0.51% | 4495 | 0.41% | 2018-07-31 |
| First Trust NYSE Arca Biotech ETF | 1073678 | 0.46% | -- | -- | 2018-09-13 |
| T. Rowe Price Instl Large Cap Growth | 734970 | 0.35% | -- | -- | 2018-03-31 |
| T. Rowe Price Growth Stock | 2715600 | 1.28% | -160700 | -5.59% | 2018-03-31 |
| T. Rowe Price New Horizons | 998597 | 0.47% | -35700 | -3.45% | 2018-03-31 |
| VA CollegeAmerica Grth Fund of Amer 529F | 916000 | 0.43% | -- | -- | 2018-03-31 |
| American Funds NVIT Asset Allocation II | 764450 | 0.36% | -- | -- | 2018-03-31 |
| VA CollegeAmerica Smcap World 529E | 1088122 | 0.52% | -- | -- | 2017-12-31 |
| American Funds NVIT Growth II | 1040000 | 0.49% | -- | -- | 2017-09-30 |
| Brown Capital Mgmt Small Co Inv | 1233990 | 0.66% | -- | -- | 2017-01-31 |
| Vanguard Extended Market Idx Inv | 2075367 | 1.10% | 67078 | 3.34% | 2016-12-31 |
| American Funds NVIT Growth | 3917500 | 2.10% | -757500 | -16.20% | 2015-09-30 |
| VA CollegeAmerica New Perspective | 3836800 | 2.10% | -- | -- | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 3833164 | 2.10% | 236750 | 6.60% | 2015-10-31 |
| VA CollegeAmerica Growth Fund of America | 3333000 | 1.80% | -512100 | -13.30% | 2015-09-30 |
| T. Rowe Price New Horizons Fund | 1969300 | 1.10% | -171200 | -8.00% | 2015-09-30 |
| VA CollegeAmerica Small Cap World | 4054883 | 2.20% | -150117 | -3.60% | 2015-09-30 |
| Vanguard Extended Market Index Fund | 1690798 | 0.90% | 22125 | 1.30% | 2015-10-31 |
| Julian Charles Baker | Mr. Julian C. Baker is a Lead Independent Director at Genomic Health, Inc., Incyte Corp., a Co-Managing Member at Baker Bros. Advisors LP, a Managing Member at Baker Bros. Advisors GP LLC and a Partner at FBB Associates. He is on the Board of Directors at ACADIA Pharmaceuticals, Inc., Genomic Health, Inc. and Incyte Corp. Mr. Baker was previously employed as an Independent Director by Idera Pharmaceuticals, Inc., a Member by Credit Suisse First Boston Corp., a Principal by CSFB Private Equity Partners LLC, and an Advisory Board Member by Elm Street Venture Advisors, Inc. He also served on the board at Trimeris, Inc., Neurogen Corp., Theravance, Inc. and Presidio Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University. |
|---|---|
| Wendy L. Dixon | Wendy L. Dixon is Chairman at Sesen Bio, Inc. and President for Great Meadow Consulting LLC. She is also on the board of 5 other companies. In the past she held the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. Wendy L. Dixon received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge. |
| Christiana Stamoulis | Presently, Christiana Stamoulis is Chief Financial Officer & Executive Vice President of Incyte Corp. She is also on the board of Hologic, Inc. In her past career she held the position of President & Chief Financial Officer of Unum Therapeutics, Inc., Managing Director-Investment Banking Division at Citigroup, Inc., Senior VP-Strategy & Business Development at Vertex Pharmaceuticals, Inc. and Vice President for Goldman Sachs & Co. LLC. Ms. Stamoulis received an undergraduate degree from Massachusetts Institute of Technology and an MBA from MIT Sloan School of Management. |
| Barry P. Flannelly | Barry P. Flannelly is on the board of Genomic Health, Inc. and Executive Vice President & General Manager at Incyte Corp. In the past he held the position of Chief Executive Officer at OSS Healthcare, Inc., Vice President of Nektar Therapeutics and Senior Vice President-Commercial at Onyx Pharmaceuticals, Inc. Dr. Flannelly received a doctorate from the University of Maryland School of Pharmacy, an MBA from the University of Baltimore and an undergraduate degree from Massachusetts College of Pharmacy & Health Science. |
| Jean-Jacques Bienaim�0�1�0�8 | Jean-Jacques Bienaim�0�1�0�8 holds the position of Chairman & Chief Executive Officer of BioMarin Pharmaceutical, Inc. He is also on the board of Incyte Corp., Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. In the past he occupied the position of Lead Independent Director at NeurogesX, Inc., President & Chief Executive Officer at SangStat Medical Corp., Chairman, President & Chief Executive Officer at Genencor International, Inc., Director-Cardiopulmonary Products Marketing at Genentech, Inc. and Vice President & General Manager at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Jean-Jacques Bienaim�0�1�0�8 received an undergraduate degree from ESCP Europe Campus Paris, an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from The University of Texas. |
| David W. Gryska | Currently, David W. Gryska is Chief Financial Officer & Executive Vice President of Incyte Corp. He is also on the board of Seattle Genetics, Inc., Aerie Pharmaceuticals, Inc. and PDL BioPharma, Inc. In his past career Mr. Gryska occupied the position of President, CEO, COO & Director at Myrexis, Inc., Chief Financial Officer & Senior Vice President for Celgene Corp., Principal at Strategic Consulting Group, Inc., Chief Financial Officer & Vice President for Cardiac Pathways Corp., Chief Financial Officer & Senior Vice President at Scios, Inc. and Partner at Ernst & Young LLP. He received an undergraduate degree from Loyola University of Chicago and an MBA from Golden Gate University. |
| Paul Alan Brooke | Mr. Paul A. Brooke is Co-Founder & Managing Partner at venBio Partners LLC, Independent Director at Incyte Corp., Managing Member at PMSV Holdings LLC, Principal at Cheyne Capital LLC, Investment Advisor at Barrett, Vernon, Montgomery LLC, Senior Advisor at Morgan Stanley & Co. LLC, and Partner at venBio Select Advisor LLC. He is on the Board of Directors at Cytos Biotechnology AG, Incyte Corp., HoustonPharma, Inc., and LifeSync Holdings, Inc. Mr. Brooke was previously employed as Chairman by Alsius Corp. and Alsius Corp., Chairman & Chief Executive Officer by Ithaka Acquisition Corp., Managing Director by Tiger Management LLC and Morgan Stanley & Co., Inc., Venture Partner by MPM Capital LP, and Principal by Morgan Stanley Japan Ltd. He also served on the board at WebMD Health Corp., GMP Cos., Inc., Emdeon Corp., HLTH Corp., Manning & Napier, Inc., MPM BioEquities Adviser LLC, Novirio Pharmaceuticals, Inc., TransForm Pharmaceuticals, Inc., and WebMD, Inc. Mr. Brooke received his BA, Cum Laude, from Columbia College and MA from Columbia University. |
| Paul A. Friedman | Currently, Paul A. Friedman is Chairman, President & Chief Executive Officer of Madrigal Pharmaceuticals, Inc. He is also on the board of Incyte Corp. (former President, Chief Executive Officer & Director), Alexion Pharmaceuticals, Inc. and Gliknik, Inc. and Member of American Society for Pharmacology & Experimental Therapeutic, Member of American Society for Biochemistry & Molecular Biology, Inc. and Member of American Society for Clinical Investigation. He previously held the position of Director at Cerulean Pharma, Inc., President of DuPont Pharmaceuticals Research Laboratories, President-Research & Development at DuPont Merck Pharmaceutical Co., Senior Vice President of Merck Research Laboratories and Associate Professor at Harvard Medical School. Paul A. Friedman received an undergraduate degree from Princeton University and a doctorate from Harvard Medical School. |
| Paula J. Swain | Paula J. Swain occupies the position of Executive Vice President-Human Resources for Incyte Corp. Ms. Swain is also on the board of Wilmington Renaissance Corp. and Delaware BioScience Association. In the past she occupied the position of Senior Vice President-Human Resources at Bristol-Myers Squibb Co. and Senior Vice President-Human Resources at DuPont Pharmaceuticals Co. (a subsidiary of Bristol-Myers Squibb Co.). Paula J. Swain received an undergraduate degree from Rockhurst University and an undergraduate degree from Harvard Business School. |
| Lothar H. Finke | Lothar H. Finke is Head-Clinical Development & General Manager-Japan at Incyte Corp. In the past he was Chief Medical Officer at Argos Therapeutics, Inc., Principal at Merck KGaA Principal at Lexigen Pharmaceuticals Corp. and Principal at EMD Pharmaceuticals, Inc. (both are subsidiaries of Merck KGaA) and Principal at Basel Institute for Immunology. He received a doctorate from Philipps University of Marburg. |
| Jacqualyn A. Fouse | Jacqualyn A. Fouse is an American businessperson who has been at the head of 5 different companies. Currently, Dr. Fouse is Chief Executive Officer & Director at Agios Pharmaceuticals, Inc. Dr. Fouse is also on the board of Incyte Corp. and Dick's Sporting Goods, Inc. In the past she was Executive Chairman of Roivant Sciences GmbH, President, Chief Operating Officer & Director at Celgene Corp., Chief Financial Officer of Bunge Ltd., Senior VP, Chief Financial & Strategy Officer at Alcon, Inc. and Chief Financial Officer & SVP-Corporate Strategy at Alcon Laboratories, Inc. (a subsidiary of Alcon, Inc.), Group Treasurer at Nestl�0�1�0�8 SA, Executive Chairman for Axovant Gene Therapies Ltd., Executive Chairman for Dermavant Sciences, Inc., Chief Financial Officer for Swissair Group, Principal at LTV Aerospace & Defense Co. and Principal at Celanese Chemicals, Inc. Dr. Fouse received a graduate degree, a doctorate and an undergraduate degree from The University of Texas at Arlington. |
| Michael Charles A. Booth | Presently, Michael Charles A. Booth occupies the position of Vice President-Investor Relations at Incyte Corp. In his past career he was Member-Management Board at Trout International LLC, Research Analyst at Canaccord Adams Ltd. and Senior VP-Communications & Corporate Affairs at Algeta ASA. He received an undergraduate degree from the University of St. Andrews and a doctorate from the University of Oxford. |
| Paul J. Clancy | Presently, Paul J. Clancy occupies the position of Chief Financial Officer & Executive Vice President of Alexion Pharmaceuticals, Inc., President & Director at Bioverativ Therapeutics, Inc. and Secretary, Director & Vice President at Stromedix, Inc. Mr. Clancy is also on the board of Incyte Corp. and Agios Pharmaceuticals, Inc. Paul J. Clancy previously was Chief Financial Officer & Executive Vice President for Biogen, Inc. Chief Financial Officer & Executive Vice President at Biogen Idec New Ventures, Inc. and Chief Financial Officer of Biogen Idec, Inc. (North Carolina) (both are subsidiaries of Biogen, Inc.) and VP & General Manager-Great West Business Unit at PepsiCo, Inc. Mr. Clancy received an undergraduate degree from Babson College and an MBA from Columbia Business School. |
| Wendy L. Dixon | Wendy L. Dixon is Chairman at Sesen Bio, Inc. and President for Great Meadow Consulting LLC. She is also on the board of 5 other companies. In the past she held the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. Wendy L. Dixon received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge. |
| Reid M. Huber | Currently, Reid M. Huber is Chief Scientific Officer & Executive VP at Incyte Corp. He is also on the board of Bellicum Pharmaceuticals, Inc. He previously held the position of Principal Research Scientist at DuPont Pharmaceuticals Co. He received an undergraduate degree from Murray State University (Kentucky) and a doctorate from the University of Washington. |
| Wenqing Yao | Wenqing Yao is Executive Vice President-Discovery Chemistry at Incyte Corp. He previously occupied the position of Principal Scientist at Bristol-Myers Squibb Co. and Principal Scientist at DuPont Pharmaceuticals Co. (a subsidiary of Bristol-Myers Squibb Co.). Dr. Yao received an undergraduate degree from Xuzhou Normal University, a graduate degree from Nankai University and a doctorate from the University of Pennsylvania. |
| Robert Newton | Robert Newton is Vice President-Drug Discovery Biology at Incyte Corp. |
| Kim Solomon | Kim Solomon is Vice President-Project Management at Incyte Corp. |
| Herv�0�1�0�8 Hoppenot | Presently, Herv�0�1�0�8 Hoppenot is Chairman, President & Chief Executive Officer at Incyte Corp. Mr. Hoppenot is also on the board of Biotechnology Innovation Organization, Cellectis SA and Pharmaceutical Research & Manufacturers of America. Mr. Hoppenot previously occupied the position of President for Novartis Oncology, Inc., President of Novartis Pharmaceuticals Corp., Head-US Oncology Business Unit at Aventis SA, Vice President-Oncology Division at Aventis Pharmaceuticals, Inc., Principal at Rhone Poulenc AG, Inc., Head-Product Strategy & Scientific Development at Novartis Pharmaceuticals Corp. and Head-US Oncology Business Unit at Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
| Keith Mikkelson | Keith Mikkelson is Executive Director-Business Development at Incyte Corp. |
| Steven H. Stein | Presently, Steven H. Stein is Chief Medical Officer & Executive Vice President at Incyte Corp. He is also on the board of Kura Oncology, Inc. In the past he was Vice President-Global Oncology at GlaxoSmithKline (New Jersey), Senior VP-US Clinical Development & Medical Affair at Novartis Pharmaceuticals Corp. and SVP-US Clinical Development & Medical Affairs at Novartis Oncology, Inc. Dr. Stein received a doctorate from the University of the Witwatersrand. |
| Holly Koblish | Holly Koblish is Associate Director at Incyte Corp. |
| Phillip Liu | Phillip Liu is Associate Director-Applied Technology at Incyte Corp. |
| Paul Trower | Paul Trower is Vice President-Finance at Incyte Corp. Mr. Trower received an undergraduate degree from Drexel University. |
| Vijay Iyengar | Vijay Iyengar holds the position of President of HistoRx, Inc. Dr. Iyengar is also EVP-Global Strategy & Corporate Development at Incyte Corp. In the past he occupied the position of Engagement Manager at McKinsey & Co., Inc., President at Genoptix, Inc., Global Brand Director-Oncology at Novartis Pharmaceuticals Corp., Vice President & General Manager at Novartis Hellas SACI and Vice President at Novartis Oncology, Inc. Dr. Iyengar received an undergraduate degree from Stanford University and a doctorate from Harvard Medical School. |
| Michael Morrissey | Michael Morrissey is Senior VP & Head-Global Technical Operations at Incyte Corp. In the past he held the position of Vice President & Head-Technical Operations at Celgene International, Inc. |
| Maria E. Pasquale | Presently, Maria E. Pasquale holds the position of Secretary, Executive VP & General Counsel of Incyte Corp. She previously held the position of Chief Counsel & Global Chief Compliance Officer at Celgene Corp. Ms. Pasquale received a graduate degree from Brooklyn Law School and an undergraduate degree from Stony Brook University. |
| Peter Langmuir | Peter Langmuir is Vice President-Oncology Drug Development at Incyte Corp. |
| Dashyant Dhanak | Dashyant Dhanak holds the position of Chief Scientific Officer & Executive VP at Incyte Corp. Dr. Dhanak previously occupied the position of Vice President & Head-Discovery Sciences at Janssen Research & Development LLC and Vice President at GlaxoSmithKline LLC. Dr. Dhanak received an undergraduate degree from the University of Manchester Institute of Science & Technology and a doctorate from the University of London. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 4
【N诚达盘中大涨71% 触发二次临停】诚达药业今日上市，午后拉升大涨超71%，较开盘价涨幅达60%触发二次临停。公司路演时称，主要为跨国制药企业及医药研发机构提供关键医药中间体CDMO服务，研发生产芦可替尼、巴瑞替尼、阿拉莫林等创新药的关键中间体，已与GSK、Evonik、Helsinn、Incyte、Gilead、辉瑞等多家终端定制客户建立了合作关系。
Incyte(INCY.O)：2021年第三季度每股盈利0.82美元，去年同期每股亏损0.07美元。
诺诚健华(09969.HK)：与Incyte就一款靶向CD19药在大中华区的开发和商业化签合作和许可合约。
【礼来制药公布新冠肺炎治疗方式试验数据 股价涨2.5%】礼来制药股价涨幅扩大至将近2.5%，逼近美股盘初录得的日高153.77美元。礼来制药与Incyte递交新版新冠肺炎病毒治疗药物的（临床）试验数据，礼来制药称，Baricitinib已经改善了治疗效果。